Antev Appoints Steven van Os as Chief Medical Officer
London, UK, 31 May 2022; Antev Ltd., a company focused on developing its GnRH1 Antagonist, teverelix, in lead indication of Advanced Prostate Cancer, is delighted to announce the appointment of Dr Steven van Os as Chief Medical Officer. He joins the executive management team with responsibility for the development of the company´s clinical portfolio in men’s health.
Dr van Os has successfully led clinical development, medical affairs and regulatory approval for drugs across several therapy areas including Oncology, Urology, Hepatology and Gynaecology. He has been associated with regulatory approvals across FDA, EMA and several other markets over an impressive career spanning more than 30 years.
“We are delighted to welcome Steve to Antev as Chief Medical Officer at this exciting and critical stage in Antev’s journey to secure regulatory approval for teverelix in Advanced Prostate Cancer and further indications”, commented Amit Kohli, Chief Executive Officer of Antev. “With compelling efficacy and safety data in the ongoing study in Advanced Prostate Cancer patients and strong support of leading scientific thought leaders, Steve’s relevant experience will ensure that the patients will have access to teverelix as soon as possible.”
Antev’s new Chief Medical Officer, Dr Steve van Os, added, “Having worked in the past on the development and registration of Xtandi for prostate cancer patients, I am now thrilled to join Antev, an agile biotech company that is developing a novel GnRH antagonist, designed to deliver improved compliance and outcomes, as a potential life-saving treatment for patients with hormone sensitive advanced prostate cancer. Working with Antev’s highly experienced team I look forward to bringing teverelix to its full potential for the treatment of prostate cancer”.
Dr van Os is a qualified medical doctor, who received his undergraduate training and his M.D. from the University of Utrecht, Netherlands. Before joining industry in 1997, Dr Van Os was a practicing physician at Hofpoort Hospital, Woerden and at Avios Health Services. Since then he has held senior leadership roles in a number of large pharmaceutical companies, including Astellas Pharma, Schering Plough, Organon International and Yamanouchi Europe. He has been involved in multiple product approvals. Most recently as co-chair of the Pfizer/ Astellas alliance, he led the global development and approval of the prostate cancer drug, Xtandi into 97 countries.
He is currently a member of the Netherlands Association of Pharmaceutical Physicians and is a member of the Dutch Board for Pharmaceutical Medicine.
